BioCryst Pharmaceuticals Inc (BCRX) stock
BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.50+0.05 (+0.67%)
Close on Nov 17, 2026Market cap $1.92BP/E –Yield –
BioCryst Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
BioCryst Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $197.76M, up 15.5% year over year. For fiscal 2025 it was $166.13M, down 4.9% from the year before. Over ten years it grew 8.6% a year on average. The highest annual figure on record is $253.30M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $166.13M | -4.9% |
| FY2024 | Dec 31, 2024 | $174.64M | -19.4% |
| FY2023 | Dec 31, 2023 | $216.57M | -14.5% |
| FY2022 | Dec 31, 2022 | $253.30M | +21.3% |
| FY2021 | Dec 31, 2021 | $208.81M | +69.8% |
| FY2020 | Dec 31, 2020 | $122.96M | +14.8% |
| FY2019 | Dec 31, 2019 | $107.07M | +26.1% |
| FY2018 | Dec 31, 2018 | $84.89M | +26.8% |
| FY2017 | Dec 31, 2017 | $66.96M | +9.8% |
| FY2016 | Dec 31, 2016 | $61.01M | -16.1% |
| FY2015 | Dec 31, 2015 | $72.76M | +40.5% |
| FY2014 | Dec 31, 2014 | $51.80M | +23.5% |
| FY2013 | Dec 31, 2013 | $41.94M | -14.7% |
| FY2012 | Dec 31, 2012 | $49.16M | -14.1% |
| FY2011 | Dec 31, 2011 | $57.25M | -31.8% |
| FY2010 | Dec 31, 2010 | $83.90M | +13.9% |
| FY2009 | Dec 31, 2009 | $73.66M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $51.97M | +19.8% |
| Q1 FY2026 | Mar 31, 2026 | $60.32M | +61.8% |
| Q4 FY2025 | Dec 31, 2025 | $40.87M | -17.3% |
| Q3 FY2025 | Sep 30, 2025 | $44.60M | +8.6% |
| Q2 FY2025 | Jun 30, 2025 | $43.39M | +15.3% |
| Q1 FY2025 | Mar 31, 2025 | $37.27M | -19.8% |
| Q4 FY2024 | Dec 31, 2024 | $49.44M | -29.4% |
| Q3 FY2024 | Sep 30, 2024 | $41.08M | -12.4% |
| Q2 FY2024 | Jun 30, 2024 | $37.62M | -26.6% |
| Q1 FY2024 | Mar 31, 2024 | $46.49M | -3.9% |
| Q4 FY2023 | Dec 31, 2023 | $70.05M | -4.3% |
| Q3 FY2023 | Sep 30, 2023 | $46.88M | -11.1% |
| Q2 FY2023 | Jun 30, 2023 | $51.25M | -17.3% |
| Q1 FY2023 | Mar 31, 2023 | $48.39M | -26.0% |
| Q4 FY2022 | Dec 31, 2022 | $73.21M | +15.2% |
| Q3 FY2022 | Sep 30, 2022 | $52.74M | +5.5% |
| Q2 FY2022 | Jun 30, 2022 | $61.99M | +17.2% |
| Q1 FY2022 | Mar 31, 2022 | $65.36M | +54.0% |
| Q4 FY2021 | Dec 31, 2021 | $63.53M | +79.7% |
| Q3 FY2021 | Sep 30, 2021 | $49.97M | +65.2% |
| Q2 FY2021 | Jun 30, 2021 | $52.87M | +92.3% |
| Q1 FY2021 | Mar 31, 2021 | $42.44M | +42.1% |
| Q4 FY2020 | Dec 31, 2020 | $35.35M | +32.0% |
| Q3 FY2020 | Sep 30, 2020 | $30.25M | +20.4% |
| Q2 FY2020 | Jun 30, 2020 | $27.50M | -0.7% |
| Q1 FY2020 | Mar 31, 2020 | $29.87M | +8.6% |
| Q4 FY2019 | Dec 31, 2019 | $26.77M | +14.3% |
| Q3 FY2019 | Sep 30, 2019 | $25.12M | +14.2% |
| Q2 FY2019 | Jun 30, 2019 | $27.68M | +31.8% |
| Q1 FY2019 | Mar 31, 2019 | $27.49M | +49.1% |
| Q4 FY2018 | Dec 31, 2018 | $23.43M | +38.4% |
| Q3 FY2018 | Sep 30, 2018 | $22.01M | +25.7% |
| Q2 FY2018 | Jun 30, 2018 | $21.01M | +33.3% |
| Q1 FY2018 | Mar 31, 2018 | $18.44M | +10.0% |
| Q4 FY2017 | Dec 31, 2017 | $16.92M | +39.2% |
| Q3 FY2017 | Sep 30, 2017 | $17.51M | +24.1% |
| Q2 FY2017 | Jun 30, 2017 | $15.76M | – |
| Q1 FY2017 | Mar 31, 2017 | $16.77M | – |
| Q4 FY2016 | Dec 31, 2016 | $12.16M | – |
| Q3 FY2016 | Sep 30, 2016 | $14.11M | – |
See a number that looks wrong?